J 2022

Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials

DANIS, Radoslav, Michal MEGO, Mariya ANTONOVA, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK et. al.

Základní údaje

Originální název

Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials

Autoři

DANIS, Radoslav (garant), Michal MEGO, Mariya ANTONOVA, Radka ŠTĚPÁNOVÁ (203 Česká republika), Adam SVOBODNÍK (203 Česká republika), Renata HEJNOVÁ (203 Česká republika, domácí) a Martin WAWRUCH

Vydání

INTEGRATIVE CANCER THERAPIES, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2022, 1534-7354

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.900

Kód RIV

RIV/00216224:14110/22:00127762

Organizační jednotka

Lékařská fakulta

UT WoS

000905190300003

Klíčová slova česky

probiotics; cancer; chemotherapy; adverse effects; diarrhea; prevention

Klíčová slova anglicky

probiotics; cancer; chemotherapy; adverse effects; diarrhea; prevention

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 19. 2. 2024 11:21, Mgr. Tereza Miškechová

Anotace

V originále

Background: Chemoradiotherapy-induced gastrointestinal toxicity may lead to a significant impairment of the oncological patient’s quality of life, as well as to reduced adherence to the treatment, which may have a negative impact on survival and mortality rates. Objective: The aim of this review was to investigate whether oral probiotic administration prevents chemotherapy (± radiotherapy)-induced gastrointestinal toxicity, particularly diarrhea. Methods: We searched the MEDLINE, Web of Science, and SCOPUS databases for randomized controlled trials in English published between 1990 and 2020. We conducted statistical data analyses expressing the treatment effect size as a risk ratio (RR) together with a 95% confidence interval (CI). Implications are based on trials rated as having a low risk of bias (RoB). Results: We included 8 trials (n=697 participants), from which 3 studies rated as low RoB contained primary endpoint data; the risk of developing grade 3/4 diarrhea in patients receiving probiotics was reduced by 78% compared to the control group (RR=0.22 [95% CI 0.05-1.08]; P=.06; n=114 participants). Probiotics showed preventive effects in patients treated with chemotherapy alone (RR=0.34 [0.12-0.94]; P=.04, n=121 participants) and in patients with colorectal cancer (RR=0.56 [0.34-0.92]; P=.02; n=208 participants). The reduction in the incidence of overall diarrhea was not significant. Conclusions: Probiotics failed to prove a preventive effect of statistical significance against the development of severe and overall diarrhea in cancer patients treated with chemotherapy (± radiotherapy). However, we cannot rule out that the effects of probiotics are clinically relevant, especially in certain subgroups of patients. This needs to be clarified in further well-performed studies.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)
Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum
90128, velká výzkumná infrastruktura
Název: CZECRIN III